A CRISPR/Cas9 startup launches on the R&D frontier, working on a one-time fix for Duchenne MD
After experimenting with CRISPR/Cas9 tech, perfecting genetic surgery on muscle cells in mice to snip out the faulty exons that are the cause of the lethal muscle wasting disease, UT Southwestern’s Eric Olson is ready to move into the late preclinical stage of development. His work is being spun out into a startup which Olson hopes will play a big role in eventually correcting the fatal genetic flaws for most of the boys who have this disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.